SCHEMBL3578730

SCHEMBL3578730

NNC(=O)c1csc2ccccc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.72
HDAC4 P56524 1/20 0.72
HDAC1 Q13547 1/20 0.72
HDAC7 Q8WUI4 1/20 0.72
HDAC2 Q92769 1/20 0.72
HDAC10 Q969S8 1/20 0.72
HDAC11 Q96DB2 1/20 0.72
HDAC8 Q9BY41 1/20 0.72
HDAC6 Q9UBN7 1/20 0.72
HDAC9 Q9UKV0 1/20 0.72
HDAC5 Q9UQL6 1/20 0.72
HPGD P15428 4/20 0.60
POLB P06746 2/20 0.60
SMN1; SMN2 Q16637 8/20 0.59
ALDH1A1 P00352 5/20 0.59
CYP1A2 P05177 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57
GAA P10253 1/20 0.57
LMNA P02545 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160488 0.83 HDAC3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25463640 0.82 HDAC3 (0.72) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL12923812 0.82 HDAC3 (0.72) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL8329059 0.81 CYP1A2 (0.72) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL29800086 0.79 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL645673 0.79 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2184154 0.79 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL20541971 0.79 HDAC3 (0.68) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL15595976 0.79 HDAC3 (0.62) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL9751612 0.79 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729269-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2014-05-20 US disclosed
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED 2010-06-10 US disclosed
US-7687627-B2 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED (IN) 2010-03-30 US disclosed
EP-1664038-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED I IN VIVO /I EFFICACY Wockhardt Limited (IN) 2006-06-07 EP disclosed
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy WOCKHARDT LIMITED 2005-06-30 US disclosed
WO-2005054234-A2 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICRIOBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY WOCKHARDT LIMITED (IN) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144735-A1 SUBSTITUTED PIPERIDINO PHENYLOXAZOLIDINONES HAVING ANTIMICROBIAL ACTIVITY WITH IMPROVED IN VIVO EFFICACY GMPS, MPO, ARG1 HDAC3 1482/4885HDAC4 525/4885HDAC1 855/4885
US-20050143421-A1 Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy GMPS, MPO, ARG1 HDAC3 1482/4885HDAC4 525/4885HDAC1 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.